AstraZeneca’s Ultomiris has been approved by the FDA to treat rare autoimmune disease neuromyelitis optica spectrum disorder (NMOSD), six months after an earlier applicati
AstraZeneca has upgraded a 2020 alliance with Fusion Pharma focusing on radioconjugate therapies for cancer, opting to buy the firm outright in a deal worth around $2 bill
AstraZeneca has added a late-stage rare disease therapy to its pipeline, buying France’s Amolyt Pharma and its hypoparathyroidism drug eneboparatide for $800 million upfro
A £650 million investment package by AstraZeneca in the UK has been held up by Chancellor Jeremy Hunt as a “vote of confidence” in the country’s life sciences sector.
As Vice President of Cancer Biomarker Development at AstraZeneca, Jorge Reis-Filho seeks to develop and validate the next generation of mechanistically informed and clinically deployable bi
NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.